Published in Neuropsychopharmacology on August 01, 2004
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
Chronic stress, drug use, and vulnerability to addiction. Ann N Y Acad Sci (2008) 4.60
Cannabis and psychosis. BMJ (2006) 2.44
High-potency cannabis and the risk of psychosis. Br J Psychiatry (2009) 2.41
Cognitive control deficits in schizophrenia: mechanisms and meaning. Neuropsychopharmacology (2010) 2.20
Human cannabinoid pharmacokinetics. Chem Biodivers (2007) 1.91
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol (2011) 1.81
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry (2012) 1.77
The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl) (2006) 1.72
Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry (2008) 1.64
Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology (2009) 1.62
From drugs to deprivation: a Bayesian framework for understanding models of psychosis. Psychopharmacology (Berl) (2009) 1.60
Psychosocial stress and psychosis. A review of the neurobiological mechanisms and the evidence for gene-stress interaction. Schizophr Bull (2008) 1.59
Cannabinoid modulation of amygdala reactivity to social signals of threat in humans. J Neurosci (2008) 1.55
Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology (2008) 1.49
Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: the role of stress and of antipsychotic treatment. Schizophr Res (2009) 1.48
Psychosis associated with acute recreational drug toxicity: a European case series. BMC Psychiatry (2016) 1.40
Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci (2009) 1.37
Glutamatergic model psychoses: prediction error, learning, and inference. Neuropsychopharmacology (2010) 1.34
Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models. Br J Pharmacol (2010) 1.33
Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. Pharmacol Biochem Behav (2010) 1.33
Developing public health regulations for marijuana: lessons from alcohol and tobacco. Am J Public Health (2014) 1.30
Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull (2013) 1.29
Cannabinoids in health and disease. Dialogues Clin Neurosci (2007) 1.28
Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology (2010) 1.19
Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia? J Psychiatry Neurosci (2007) 1.18
Gone to Pot - A Review of the Association between Cannabis and Psychosis. Front Psychiatry (2014) 1.14
Cannabinoid facilitation of fear extinction memory recall in humans. Neuropharmacology (2012) 1.14
Temporal association of cannabis use with symptoms in individuals at clinical high risk for psychosis. Schizophr Res (2008) 1.13
Differential developmental trajectories for CB1 cannabinoid receptor expression in limbic/associative and sensorimotor cortical areas. Synapse (2011) 1.13
Genetic predisposition to schizophrenia associated with increased use of cannabis. Mol Psychiatry (2014) 1.13
Prevalence of psychotic symptoms in substance users: a comparison across substances. Compr Psychiatry (2008) 1.11
Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. Schizophr Bull (2014) 1.10
Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortex. Neuroscience (2010) 1.10
Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacology (Berl) (2006) 1.10
Stress-related factors in cannabis use and misuse: implications for prevention and treatment. J Subst Abuse Treat (2008) 1.07
Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans. Biol Psychiatry (2012) 1.04
Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans. Psychopharmacology (Berl) (2008) 1.03
Substance abuse in patients with schizophrenia. Dialogues Clin Neurosci (2006) 1.02
Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci (2016) 1.01
Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Δ⁹-THC in humans. Neuropsychopharmacology (2012) 1.01
Role of cannabis and endocannabinoids in the genesis of schizophrenia. Psychopharmacology (Berl) (2009) 1.01
Biomarkers for the effects of cannabis and THC in healthy volunteers. Br J Clin Pharmacol (2009) 1.00
What makes one person paranoid and another person anxious? The differential prediction of social anxiety and persecutory ideation in an experimental situation. Psychol Med (2008) 1.00
Schizophrenia: a tale of two critical periods for prefrontal cortical development. Transl Psychiatry (2015) 0.99
How cannabis causes paranoia: using the intravenous administration of ∆9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia. Schizophr Bull (2014) 0.98
Reviewing the ketamine model for schizophrenia. J Psychopharmacol (2013) 0.96
The effect of cannabis on the brain: can it cause brain anomalies that lead to increased risk for schizophrenia? Curr Opin Psychiatry (2008) 0.95
Two cases of "cannabis acute psychosis" following the administration of oral cannabis. BMC Psychiatry (2005) 0.94
Should burden of disease estimates include cannabis use as a risk factor for psychosis? PLoS Med (2009) 0.94
Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light. Front Behav Neurosci (2011) 0.94
Chronic adolescent exposure to Δ-9-tetrahydrocannabinol in COMT mutant mice: impact on psychosis-related and other phenotypes. Neuropsychopharmacology (2010) 0.93
Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence. Neuropsychopharmacology (2011) 0.93
CB1 cannabinoid receptor stimulation during adolescence impairs the maturation of GABA function in the adult rat prefrontal cortex. Mol Psychiatry (2014) 0.93
An Introduction to the Endogenous Cannabinoid System. Biol Psychiatry (2015) 0.93
The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case histories. Psychopharmacology (Berl) (2011) 0.92
The epidemiology of schizophrenia: replacing dogma with knowledge. Dialogues Clin Neurosci (2010) 0.92
Excessive substance use in bipolar disorder is associated with impaired functioning rather than clinical characteristics, a descriptive study. BMC Psychiatry (2010) 0.92
AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder. Neuropsychopharmacology (2011) 0.92
Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users. Eur Neuropsychopharmacol (2014) 0.92
Cannabinoids and Schizophrenia: Risks and Therapeutic Potential. Neurotherapeutics (2015) 0.91
Probing GABA receptor function in schizophrenia with iomazenil. Neuropsychopharmacology (2010) 0.91
Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives. Recent Pat CNS Drug Discov (2012) 0.91
Associations of cannabis and cigarette use with psychotic experiences at age 18: findings from the Avon Longitudinal Study of Parents and Children. Psychol Med (2014) 0.91
The effects of cannabinoids on serum cortisol and prolactin in humans. Psychopharmacology (Berl) (2008) 0.91
Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis. Schizophr Bull (2015) 0.91
Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an FMRI study. Neuropsychopharmacology (2011) 0.90
Psychobiological responses to unpleasant emotions in cannabis users. Eur Arch Psychiatry Clin Neurosci (2011) 0.90
Disruption of frontal θ coherence by Δ9-tetrahydrocannabinol is associated with positive psychotic symptoms. Neuropsychopharmacology (2010) 0.89
Functional genetic variation of the cannabinoid receptor 1 and cannabis use interact on prefrontal connectivity and related working memory behavior. Neuropsychopharmacology (2014) 0.89
An Internet survey of marijuana and hot shower use in adults with cyclic vomiting syndrome (CVS). Exp Brain Res (2014) 0.89
Delta9-tetrahydrocannabivarin testing may not have the sensitivity to detect marijuana use among individuals ingesting dronabinol. Drug Alcohol Depend (2009) 0.89
Cannabis-related working memory deficits and associated subcortical morphological differences in healthy individuals and schizophrenia subjects. Schizophr Bull (2013) 0.88
Stronger evidence is needed before accepting that cannabis plays an important role in the aetiology of schizophrenia in the population. F1000 Med Rep (2013) 0.88
Modulation of the endocannabinoid system: vulnerability factor and new treatment target for stimulant addiction. Front Psychiatry (2013) 0.88
The endocannabinoid system as a target for modelling psychosis. Psychopharmacology (Berl) (2009) 0.87
Does Cannabis Cause, Exacerbate or Ameliorate Psychiatric Disorders? An Oversimplified Debate Discussed. Neuropsychopharmacology (2015) 0.87
Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol Med (2015) 0.87
Delay- and dose-dependent effects of Δ⁹-tetrahydrocannabinol administration on spatial and object working memory tasks in adolescent rhesus monkeys. Neuropsychopharmacology (2012) 0.85
Impact of Cannabis Use on the Development of Psychotic Disorders. Curr Addict Rep (2014) 0.85
Association of Cannabis Use during Adolescence, Prefrontal CB1 Receptor Signaling, and Schizophrenia. Front Pharmacol (2012) 0.85
Effects of delta-9-tetrahydrocannabinol on evaluation of emotional images. J Psychopharmacol (2012) 0.84
From real-world events to psychosis: the emerging neuropharmacology of delusions. Schizophr Bull (2009) 0.84
The effect of cannabis use on memory function: an update. Subst Abuse Rehabil (2013) 0.83
Drug models of schizophrenia. Ther Adv Psychopharmacol (2015) 0.82
Endocannabinoid system: potential novel targets for treatment of schizophrenia. Neurobiol Dis (2012) 0.82
Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol (2012) 0.82
The impact of cannabis use on clinical outcomes in recent onset psychosis. Schizophr Bull (2014) 0.82
Cannabidiol Counteracts Amphetamine-Induced Neuronal and Behavioral Sensitization of the Mesolimbic Dopamine Pathway through a Novel mTOR/p70S6 Kinase Signaling Pathway. J Neurosci (2016) 0.81
Dopamine response to psychosocial stress in chronic cannabis users: a PET study with [11C]-+-PHNO. Neuropsychopharmacology (2012) 0.81
Exogenous and endogenous cannabinoids suppress inhibitory neurotransmission in the human neocortex. Neuropsychopharmacology (2011) 0.81
A protocol for the delivery of cannabidiol (CBD) and combined CBD and ∆9-tetrahydrocannabinol (THC) by vaporisation. BMC Pharmacol Toxicol (2014) 0.81
Assessing causality in associations between cannabis use and schizophrenia risk: a two-sample Mendelian randomization study. Psychol Med (2016) 0.81
Neuroimaging evidence for cannabinoid modulation of cognition and affect in man. Front Behav Neurosci (2012) 0.81
Acute effects of THC on time perception in frequent and infrequent cannabis users. Psychopharmacology (Berl) (2012) 0.81
Cannabinoid modulation of functional connectivity within regions processing attentional salience. Neuropsychopharmacology (2014) 0.81
Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence. Subst Abuse (2015) 0.80
AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. Psychopharmacology (Berl) (2010) 0.80
Analyzing the impact of social factors on homelessness: a fuzzy cognitive map approach. BMC Med Inform Decis Mak (2013) 0.80
Effects of Δ-THC on Working Memory: Implications for Schizophrenia? Prim psychiatry (2009) 0.80
Sudden death and use of stimulant medications in youths. Am J Psychiatry (2009) 4.33
Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry (2004) 3.64
Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab (2003) 3.21
NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) (2003) 2.28
Cocaine dependence and d2 receptor availability in the functional subdivisions of the striatum: relationship with cocaine-seeking behavior. Neuropsychopharmacology (2004) 2.24
Rates of violence in patients classified as high risk by structured risk assessment instruments. Br J Psychiatry (2014) 2.22
Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry (2005) 2.14
Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment. J Am Acad Child Adolesc Psychiatry (2009) 2.13
Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: short-term efficacy and adverse effects. Arch Gen Psychiatry (2009) 2.08
Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry (2002) 2.01
Human tobacco smokers in early abstinence have higher levels of beta2* nicotinic acetylcholine receptors than nonsmokers. J Neurosci (2006) 1.99
Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism. Am J Psychiatry (2004) 1.96
Investigating the behavioral and self-report constructs of impulsivity domains using principal component analysis. Behav Pharmacol (2009) 1.90
Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res (2007) 1.86
Transcranial magnetic stimulation of left temporoparietal cortex and medication-resistant auditory hallucinations. Arch Gen Psychiatry (2003) 1.81
Impairment of working memory maintenance and response in schizophrenia: functional magnetic resonance imaging evidence. Biol Psychiatry (2008) 1.76
Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. Biol Psychiatry (2004) 1.71
Cognitive-behavioral therapy for pathological gamblers. J Consult Clin Psychol (2006) 1.70
Preliminary evidence for medication effects on functional abnormalities in the amygdala and anterior cingulate in bipolar disorder. Psychopharmacology (Berl) (2005) 1.67
Impaired visual cortical plasticity in schizophrenia. Biol Psychiatry (2012) 1.67
Pharmacological strategies in the prevention of relapse after electroconvulsive therapy. J ECT (2013) 1.62
Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety. J Clin Psychiatry (2015) 1.62
DNMT3A mutation is a poor prognosis biomarker in AML: results of a meta-analysis of 4500 AML patients. Leuk Res (2013) 1.60
Extracellular metabolites in the cortex and hippocampus of epileptic patients. Ann Neurol (2005) 1.55
Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biol Psychiatry (2005) 1.55
beta2-Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. Arch Gen Psychiatry (2009) 1.53
Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry (2005) 1.52
Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry (2005) 1.52
Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology (2008) 1.49
Cognitive-behavioral therapy, behavioral weight loss, and sequential treatment for obese patients with binge-eating disorder: a randomized controlled trial. J Consult Clin Psychol (2011) 1.43
Early detection of periodic sharp wave complexes on EEG by independent component analysis in patients with Creutzfeldt-Jakob disease. J Clin Neurophysiol (2008) 1.42
Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) (2004) 1.38
Sex, GABA, and nicotine: the impact of smoking on cortical GABA levels across the menstrual cycle as measured with proton magnetic resonance spectroscopy. Biol Psychiatry (2005) 1.33
Impaired GABA neuronal response to acute benzodiazepine administration in panic disorder. Am J Psychiatry (2004) 1.20
Glutamatergic modulation of auditory information processing in the human brain. Biol Psychiatry (2011) 1.20
Brain morphological changes associated with cyclic menstrual pain. Pain (2010) 1.17
Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients. Am J Psychiatry (2007) 1.17
Dopamine beta-hydroxylase gene (DbetaH) -1021C-->T influences self-reported paranoia during cocaine self-administration. Biol Psychiatry (2006) 1.13
Changes in US antidepressant and antipsychotic prescription patterns during a period of FDA actions. Pharmacoepidemiol Drug Saf (2010) 1.12
Cortical gamma-aminobutyric acid levels and the recovery from ethanol dependence: preliminary evidence of modification by cigarette smoking. Biol Psychiatry (2005) 1.10
Luteal-phase accentuation of acoustic startle response in women with premenstrual dysphoric disorder. Neuropsychopharmacology (2007) 1.08
123I-5-IA-85380 SPECT imaging of nicotinic acetylcholine receptor availability in nonsmokers: effects of sex and menstrual phase. J Nucl Med (2007) 1.08
Preliminary evidence of reduced occipital GABA concentrations in puerperal women: a 1H-MRS study. Psychopharmacology (Berl) (2006) 1.06
Multidimensionality of the Alcohol Withdrawal Symptom Checklist: a factor analysis of the Alcohol Withdrawal Symptom Checklist and CIWA-Ar. Alcohol Clin Exp Res (2007) 1.05
Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res (2003) 1.04
Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans. Psychopharmacology (Berl) (2008) 1.03
Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol Clin Exp Res (2007) 1.03
The impact of NMDA receptor blockade on human working memory-related prefrontal function and connectivity. Neuropsychopharmacology (2013) 1.02
Gelatin "shots" as a new method for alcohol administration in a laboratory setting. Alcohol Clin Exp Res (2006) 1.02
Posttraumatic stress disorder and substance use in inner-city adolescent girls. J Nerv Ment Dis (2003) 1.01
Brain-specific change in alternative splicing of Tau exon 6 in myotonic dystrophy type 1. Biochim Biophys Acta (2005) 1.01
Noradrenergic vs serotonergic antidepressant with or without naltrexone for veterans with PTSD and comorbid alcohol dependence. Neuropsychopharmacology (2011) 1.00
A paradigm to investigate the self-regulation of cocaine administration in humans. Psychopharmacology (Berl) (2005) 0.99
Multidose risperidone treatment evaluated in a rodent model of tardive dyskinesia. Neuropsychopharmacology (2005) 0.98
Recognition of motor imagery electroencephalography using independent component analysis and machine classifiers. Ann Biomed Eng (2005) 0.97
Imaging mass spectrometry--a new and promising method to differentiate Spitz nevi from Spitzoid malignant melanomas. Am J Dermatopathol (2012) 0.97
Hemodynamic segmentation of MR brain perfusion images using independent component analysis, thresholding, and Bayesian estimation. Magn Reson Med (2003) 0.96
Neuronal correlates of consistency and frequency effects on Chinese character naming: an event-related fMRI study. Neuroimage (2004) 0.96
Risk factors for cocaine-induced paranoia in cocaine-dependent sibling pairs. Drug Alcohol Depend (2006) 0.96
Using computational patients to evaluate illness mechanisms in schizophrenia. Biol Psychiatry (2011) 0.95
The effect of early trauma exposure on serotonin type 1B receptor expression revealed by reduced selective radioligand binding. Arch Gen Psychiatry (2011) 0.95
Neuronal correlates in the modulation of placebo analgesia in experimentally-induced esophageal pain: a 3T-fMRI study. Pain (2009) 0.94
Self-reported paranoia during laboratory "binge" cocaine self-administration in humans. Pharmacol Biochem Behav (2006) 0.94
Cortical gamma-aminobutyric acid type A-benzodiazepine receptors in recovery from alcohol dependence: relationship to features of alcohol dependence and cigarette smoking. Arch Gen Psychiatry (2005) 0.94
Inter-rater reliability and concurrent validity of DSM-IV opioid dependence in a Hmong isolate using the Thai version of the Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA). Addict Behav (2010) 0.93
Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2004) 0.93
The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case histories. Psychopharmacology (Berl) (2011) 0.92
Spatiotemporal brain dynamics in response to muscle stimulation. Neuroimage (2005) 0.92
Impairments in cognitive function and brain connectivity in severe asymptomatic carotid stenosis. Stroke (2012) 0.92
Event-related functional MRI study on central representation of acute muscle pain induced by electrical stimulation. Neuroimage (2002) 0.92
Cortisol levels in relation to hippocampal sub-regions in subjects with first episode schizophrenia. Schizophr Res (2007) 0.91
The effects of cannabinoids on serum cortisol and prolactin in humans. Psychopharmacology (Berl) (2008) 0.91
Enhanced sensitivity to the euphoric effects of alcohol in schizophrenia. Neuropsychopharmacology (2006) 0.90
Visitor perceptions of rural landscapes: a case study in the Peak District National Park, England. J Environ Manage (2008) 0.89
Brain β2*-nicotinic acetylcholine receptor occupancy after use of a nicotine inhaler. Int J Neuropsychopharmacol (2010) 0.89
Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans. Psychopharmacology (Berl) (2008) 0.89
Mutual-information-based approach for neural connectivity during self-paced finger lifting task. Hum Brain Mapp (2008) 0.89
Morphological regionalization using fetal magnetic resonance images of normal developing brains. Eur J Neurosci (2009) 0.88
Co-activation of primary motor cortex ipsilateral to muscles contracting in a unilateral motor task. Clin Neurophysiol (2013) 0.88
Addition of the alpha2-antagonist yohimbine to fluoxetine: effects on rate of antidepressant response. Neuropsychopharmacology (2004) 0.88
The brain computer interface using flash visual evoked potential and independent component analysis. Ann Biomed Eng (2006) 0.88
Pyridine and pyrimidine analogs of acetaminophen as inhibitors of lipid peroxidation and cyclooxygenase and lipoxygenase catalysis. Org Biomol Chem (2009) 0.88